From: Initial study on TMPRSS2 p.Val160Met genetic variant in COVID-19 patients
Variables | Asymptomatic (N=21) | Mild (N=12) | Moderate (N=32) | Severe (N=30) | All patients (N=95) | P value chi-square test (unless otherwise stated) |
---|---|---|---|---|---|---|
Age (years) | 33.9 ± 2.4* | 35.6 ± 2.7* | 52.3 ± 2.1 | 48.8 ± 1.5 | 44.7 ± 1.3 | *P<0.001 versus moderate and severe groups (ANOVA) |
Gender (%) | ||||||
 Male | 8 (38.1%) | 10 (83.3%) | 19 (59.4%) | 23 (76.7%) | 60 (63.2%) | 0.016 |
 Female | 13 (61.9%) | 2 (16.7%) | 13 (40.6%) | 7 (23.3%) | 35 (36.8%) |  |
Underlying diseases (%) | ||||||
 Diabetes | 0 | 0 | 9 (28.1%) | 12 (40%) | 21 (22.1%) | <0.001 |
 CVD | 2 (9.5%) | 0 | 13 (40.6%) | 10 (33.3%) | 25 (26.3%) | 0.009 |
 Liver diseases | 0 | 0 | 4 (12.5%) | 9 (30%) | 13 (13.7%) | 0.007 |
 Kidney diseases | 0 | 0 | 4 (12.5%) | 1 (3.3%) | 5 (5.3%) | 0.144 |
 Lung diseases | 0 | 0 | 3 (9.4%) | 0 | 3 (3.2%) | 0.107 |
 Others | 0 | 0 | 3 (9.4%) | 2 (6.7%) | 5 (5.3%) | 0.386 |